

# Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 15 March 2021

## Situation Report No. 247 - Kingdom of Bahrain

16<sup>th</sup> of March, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
<b>Total</b>	119,791,453	2,652,966	6,933,453	151,097
<b>New</b>	844,656 in 2 days	15,348 in 2 days	67,252 in 2 days	962 in 2 days

### Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
	<b>Total</b>	131,683	124,823	485	6,375	61
<b>New</b>	1,279 in 2 days	1,152 in 2 days	4 in 2 days	-	-	31,871 in 2 days

### HIGHLIGHTS

- The Mortality were: 2 Male Bahraini citizens (52 and 87 years old) and 2 Male expatriates (50 and 59 years old).
- Increasing number of citizens and residents continue to take COVID-19 vaccine in Bahrain; and Ministry of Health (MOH) revealed the total number of individuals vaccinated as of 13 March 2021 for the first dose (345,970) and for the second dose (216,385).
- MOH Undersecretary indicated that Bahrain is continuing with its mitigation efforts and once again stressed the importance of adhering to precautionary measures particularly given the ease of restrictions on certain activities.
- MOH Undersecretary acknowledged that COVID-19 vaccines are a pathway to normalcy return, highlighting successes of National Vaccination Campaign's in working with manufacturers to make vaccines available for all citizens and residents free of charge, recent success include the delivery of 300,000 doses of Sinopharm vaccines.
- MOH Undersecretary noted that the Kingdom's vaccine uptake plan is evolving, but remains focused on reaching vulnerable groups at greatest risk of developing complications from COVID-19, including those 70 and those with underlying conditions.
- MOH Undersecretary revealed current COVID-19 recovery rate at 94.84% with about 0.37% case fatality rate (CFR); while occupancy at isolation centers stands at 27% with 1,502 beds occupied out of 5,569 available; and 4,750 asymptomatic cases are under optional home self-isolation.
- BDH Hospital noted that vaccines reduce the risk of serious complications associated with COVID-19, including death and in slowing existing and new Coronavirus variants.
- BDH Hospital affirmed that the groups hospitalization rates varied significantly with only 8% of vaccinated individuals admitted to hospital.
- Salmaniya Medical Complex (SMC) urged everyone to register for vaccination by visiting: <https://healthnet.gov.bh/en/>, including pregnant women and breastfeeding mothers.
- SMC: reviewed the health status of active cases, confirming 6,193 stable cases from a total of 6,352 active cases. Currently, 111 COVID-19 cases are receiving hospital treatment, of which 61 are in a critical condition.
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies; see link below.
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GIRS; see link below.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidturn assay; see link below.
- WHO: Global TB progress a trisk; see link below.
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GIRS; see link below.
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic; see link below.
- WHO: The push for a COVID-19 vaccine; see link below.
- WHO: ICMAA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines; see link below.
- WHO: Living Guidelines: The rapid and COVID-19; see link below.
- WHO: Interim guidance on Diagnostics, Therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector; see link below.
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response; see link below.
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgence or similar public health crises; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 place-bo controlled vaccine trials and trial unblinding; see link below.
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021; see link below.
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages; see link below.
- WHO: Issues its first emergency use authorization for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZenca; see link below.
- WHO: Rotavirus vaccines made available for use in humanitarian crises; see link below.
- WHO: COVID-19 Virtual Press conference transcript; see link below.
- WHO: Draft landscape and tracker of COVID-19 candidate vaccines; see link below.
- WHO: Access to COVID-19 tools funding commitment tracker; see link below.
- WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic; see link below.


### IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO COVID-19 weekly situation reports: [https://www.who.int/docs/default-source/coronavirus/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=6d49a76\\_4](https://www.who.int/docs/default-source/coronavirus/situation-reports/20200817-weekly-epi-update-1.pdf?sfvrsn=6d49a76_4)
- WHO COVID-19 Dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies: <https://www.who.int/news-room/detail/01-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Guidance on informing vaccination programs: a guide to the design and conduct of engagement surveys: <https://www.who.int/publications/item/978-92-4-151358-9>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/25vd8rI>
- WHO: Emergency Global Supply Chain System (COVID-19) catalogue: [https://www.who.int/publications/item/emergency-global-supply-chain-system-\(covid-19\)-catalogue](https://www.who.int/publications/item/emergency-global-supply-chain-system-(covid-19)-catalogue)
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapidturn assays: <https://bit.ly/30Y0J9F>
- WHO: Global TB progress a trisk: <https://bit.ly/346LH1H>
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://20w.net>
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GIRS: <https://bit.ly/344R6SG>
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic: <https://bit.ly/31QJDF2>
- WHO: As COVID-19 spread accelerates, JH Emergency Committee urges focus on measures that work: <https://bit.ly/37206>
- WHO: The push for a COVID-19 vaccine: <https://bit.ly/3n3Ba>
- WHO: ICMAA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines: <https://bit.ly/3n3Ba>
- WHO: Living Guidelines: The rapid and COVID-19: <https://www.who.int/publications/item/therapeutics-and-covid-19-living-guideline>
- WHO: Interim guidance on Diagnostics, Therapeutics, vaccine readiness, and other health products for COVID-19: [https://www.who.int/publications/item/WHO-2019-nCoV-HCWF\\_assessment-Products-2020.1](https://www.who.int/publications/item/WHO-2019-nCoV-HCWF_assessment-Products-2020.1)
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector: <https://www.who.int/publications/item/evidence-to-recommendation-covid-19-mitigation-in-the-aviation-sector>
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response: [https://20w.net/Content/Download/WHO-2019-nCoV-Health\\_workforce\\_2020.1-eng.pdf](https://20w.net/Content/Download/WHO-2019-nCoV-Health_workforce_2020.1-eng.pdf)
- WHO: Checklist to support schools re-opening and preparation for COVID-19 resurgence or similar public health crises: <https://www.who.int/publications/item/9789240017467>
- WHO: COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/item/960537953>
- WHO: Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 place-bo controlled vaccine trials and trial unblinding: <https://www.who.int/publications/item/WHO-2019-nCoV-EU-Phase-ethical-considerations-vaccine-trials-2020.1>
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19: <https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based-international-travel-2020.1>
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: [https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based-international-travel-Assessment\\_tool-2020.1](https://www.who.int/publications/item/WHO-2019-nCoV-Risk-based-international-travel-Assessment_tool-2020.1)
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021: <https://www.who.int/news/item/18-12-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021>
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages: [https://www.who.int/publications/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-\(covid-19\)-and-considerations-during-severe-shortages](https://www.who.int/publications/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-(covid-19)-and-considerations-during-severe-shortages)
- WHO: Issues its first emergency use authorization for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/item/11-12-2020-who-issues-its-first-emergency-use-authorization-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZenca: <https://www.who.int/publications/item/background-document-on-the-azd1222-vaccine-against-covid-19-developed-by-oxford-university-and-astrazenca>
- WHO: Rotavirus vaccines made available for use in humanitarian crises: <https://www.who.int/news/item/04-03-2021-rotavirus-vaccines-made-available-for-use-in-humanitarian-crisis>
- WHO: COVID-19 Virtual Press conference transcript: <https://www.who.int/publications/item/covid-19-virtual-press-conference-transcript--8-march-2021>
- WHO: Draft landscape and tracker of COVID-19 candidate vaccines: <https://www.who.int/publications/item/draft-landscape-of-covid-19-candidate-vaccines>
- WHO: Access to COVID-19 tools funding commitment tracker: <https://www.who.int/publications/item/access-to-covid-19-tools-tracker>
- WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic: <https://www.who.int/news/item/16-03-2021-new-research-highlights-risks-of-separating-newborns-from-mothers-during-covid-19-pandemic>


### IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: [NAI5@health.gov.bh](mailto:NAI5@health.gov.bh)
- International Health Regulations focal person is Dr. Kubra Salman, email: [knasser@health.gov.bh](mailto:knasser@health.gov.bh)

Number of New Cases



Total Number of Cases



Number of New Deaths

